Mark Rutstein, MD Bio
Mark Rutstein, MD
As Head of the Therapeutic Area (TA) Oncology, Mark is accountable for the development strategy of our late-stage oncology portfolio as well as for the operational delivery of both early and late-stage clinical trials. Mark oversees and provides guidance to Clinical Sciences, Clinical Operations, Biostatistics and Data Management and late-stage Clinical Development to support the advancement of our drug pipeline.
Before his current role, Mark was the Head of Oncology Clinical Development at Daiichi Sankyo. Prior to joining Daiichi Sankyo, he held various pharmaceutical positions, including roles in oncology drug development at Amgen, Eli Lilly, Bayer, and Bristol-Myers Squibb. Immediately before joining Daiichi Sankyo, he served as Vice President of Oncology Development at Bristol-Myers Squibb, overseeing the development of several oncology medicines across multiple clinical indications.
Mark has a passion for developing high performing cross-functional teams and inspiring people to be the best version of themselves to make a difference for patients. He is driven with urgency to deliver new medicines to cancer patients with a high unmet clinical need.